Metabolism and Excretion of Liraglutide in Healthy Male Volunteers

Sponsor
Novo Nordisk A/S
Study ID
NCT01517568
Phase
PHASE1
Status
Completed

Conditions

  • Diabetes
  • Healthy

Eligibility Criteria

Sex
MALE
Age
30 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide [3H] — DRUG
    A single dose of 0.75 mg will be given as a subcutaneous injection

Study Details

This trial is conducted in Europe. The aim of this trial is characterise the metabolic profile of liraglutide in plasma, urine, and faeces after a single injection of \[3H\]-liraglutide.

Key Dates

Start date
Nov 30, 2006
Status verified
Jan 2017
Primary completion
Dec 31, 2006
Completion
Dec 31, 2006

Study Design

Enrollment
7 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide

Primary Outcome Measure

Profile and identity of the major metabolites of tritium labelled liraglutide in plasma, urine, and faeces

Related Studies